SCHEMBL3268499

SCHEMBL3268499

O=C(Nc1cccnc1)N1CCN(c2cc(-c3cccc(F)c3F)ccn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.54
MAPK10 P53779 7/20 0.49
WNT1 P04628 1/20 0.49
DYRK1A Q13627 1/20 0.49
TRPV1 Q8NER1 3/20 0.49
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
DRD3 P35462 1/20 0.46
CYP11B2 P19099 1/20 0.44
PI4KB Q9UBF8 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269417 0.87 FAAH (0.71) FAAHMAPK10TRPV1KDM4EALDH1A1
SCHEMBL3275452 0.87 TRPV1 (0.52) FAAHWNT1DYRK1ATRPV1DRD2
SCHEMBL3273934 0.86 FAAH (0.54) FAAHWNT1DYRK1ATRPV1KDM4E
SCHEMBL3268546 0.85 FAAH (0.53) FAAHTRPV1KDM4EALDH1A1PI4KB
SCHEMBL3267793 0.85 FAAH (0.53) FAAHWNT1DYRK1ATRPV1KDM4E
SCHEMBL3442392 0.83 FAAH (0.59) FAAHMAPK10TRPV1KDM4EALDH1A1
SCHEMBL3269929 0.83 FAAH (0.77) FAAHMAPK10TRPV1
SCHEMBL3269630 0.81 FAAH (0.71) FAAHTRPV1ALDH1A1PI4KB
SCHEMBL3274064 0.80 FAAH (0.58) FAAHTRPV1KDM4EALDH1A1DRD2
SCHEMBL3765881 0.79 FAAH (0.54) FAAHTRPV1ALDH1A1PI4KBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
EP-2199282-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-23 EP disclosed
EP-2199282-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-23 EP disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234389-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA FAAH 1/4885MAPK10 1462/4885WNT1 4555/4885
US-20090163508-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA FAAH 1/4885MAPK10 1462/4885WNT1 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.